Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 1, 2007, Pages 1-14

  Kramer I ^a   Lipp, H P ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Angiogenesis; Antibody; Bevacizumab; Colorectal cancer; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PEGAPTANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ALOPECIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BINDING; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG STORAGE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYO DEVELOPMENT; EPISTAXIS; HEMOPTYSIS; HUMAN; HYPERTENSION; MALIGNANT TRANSFORMATION; METASTASIS; NAUSEA AND VOMITING; NONHUMAN; PERINATAL DEVELOPMENT; PROTEIN EXPRESSION; PROTEINURIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RETINA MACULA DEGENERATION; REVIEW; SOLID TUMOR; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PHYSIOLOGIC; SURVIVAL RATE;

EID: 33846834110     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00800.x     Document Type: Review

References (84)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285, 1182-1186.
2. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29, 15-18.
3. Jain RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Seminars in Oncology, 29(Suppl. 16), 3-9.
4. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nature Medicine, 9, 669-676.
5. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. The Oncologist, 9(Suppl. 1), 2-10.
6. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology, 20, 4368-4380.
7. Presta LG, Chen H, O'Connor SJ et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research, 57, 4593-4599.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335-2342.
9. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3, 401-410.
10. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nature Medicine, 6, 389-395.
11. Folkman J (2003) Fundamental concepts of the angiogenic process. Current Molecular Medicine, 3, 643-651.
12. Rosen L (2002) Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control, 9(Suppl. 2), 36-44.
13. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews, 25, 581-611.
14. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
15. Jain RK (2003) Molecular regulation of vessel maturation. Nature Medicine, 9, 685-693.
16. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nature Reviews Cancer, 2, 727-739.
17. Bergsland EK (2004) Vascular endothelial growth factor as a therapeutic target in cancer. American Journal of Health-System Pharmacy, 61, S4-S11.
18. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
19. Toi M, Matsumoto T, Bando H (2001) Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncology, 2, 667-673.
20. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011-1027.
21. Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Structure and Function, 26, 25-35.
22. Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. Journal of Biological Chemistry, 273, 13313-13316.
23. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine, 1, 1024-1028.
24. Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 1, 219-227.
25. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92, 4150-4166.
26. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. Journal of Clinical Investigation, 95, 1789-1797.
27. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research, 55, 3964-3968.
28. Tokunaga T, Oshika Y, Abe Y et al. (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. British Journal of Cancer, 77, 998-1002.
29. Ishigami SI, Arii S, Furutani M et al. (1998) Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. British Journal of Cancer, 78, 1379-1384.
30. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
31. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Research, 55, 5296-5301.
32. Inai T, Mancuso M, Hashizume H et al. (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. American Journal of Pathology, 165, 35-52.
33. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine, 7, 987-989.
34. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Current Opinion in Genetics and Development, 15, 102-111.
35. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis, 7, 225-233.
36. Lee TH, Avraham HK, Jiang S, Avraham S (2003) Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. Journal of Biological Chemistry, 278, 5277-5284.
37. Willett CG, Boucher Y, di Tomaso E et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 10, 145-147.
38. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research, 64, 3731-3736.
39. Wildiers H, Guetens G, De Boeck G et al. (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. British Journal of Cancer, 88, 1979-1986.
40. Manley PW, Bold G, Bruggen J et al. (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochimica et Biophysica Acta, 1697, 17-27.
41. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery, 3, 391-400.
42. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Research, 65, 671-680.
43. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB (2002) Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. American Journal of Pathology, 161, 1917-1924.
44. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB (2002) Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clinical Cancer Research, 8, 3226-3231.
45. Kabbinavar FF, Wong JT, Ayala RE, Wintroub AB, Kim KJ, Ferrara N (1995) The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proceedings of the American Association for Cancer Research, 36, 488 (abstract 2906).
46. Shen BQ, Stainton S, Li D, Pelletier N, Zioncheck TF (2004) Combination of Avastin™ and Xeloda® synergistically inhibits colorectal tumor growth in a COLO205 tumor xenograft model. Proceedings of the American Association for Cancer Research, 45, 508 (abstract 2203).
47. Roche (2005) Avastin summary of product characteristics. Nutley, NY: Roche.
48. Gordon MS, Margolin K, Talpaz M et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Journal of Clinical Oncology, 19, 843-850.
49. Margolin K, Gordon MS, Holmgren E et al. (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. Journal of Clinical Oncology, 19, 851-856.
50. Genentech Inc. (2005) US prescribing information. South San Francisco, CA: Genentech Inc.
51. Gaudreault J, Bruno R, Kabbinavar F, Sing A, Johnson DH, Lu J (2004) Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing. Journal of Clinical Oncology, 22(Suppl.), 205s (abstract 3041).
52. Kabbinavar FF, Schulz J, McCleod M et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. Journal of Clinical Oncology, 23, 3697-3705.
53. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 23, 3706-3712.
54. Miller KD, Wang M, Gralow J et al. (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Research and Treatment, 94(Suppl. 1), S6 (abstract 3).
55. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, Johnson DH (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. Journal of Clinical Oncology, 23(Suppl.), 2s (abstract LBA4).
56. Motl S (2005) Bevacizumab in combination chemotherapy for colorectal and other cancers. American Journal of Health-System Pharmacy, 62, 1021-1032.
57. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery Lasers and Imaging, 36, 331-335.
58. Kopetz S, Abbruzzese JL, Eng C et al. (2006) Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 24(Suppl.), 165s (abstract 3579).
59. Sobrero A, Ackland S, Carrion RP et al. (2006) Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 24(Suppl.), 157s (abstract 3544).
60. Fuchs C, Marshall J, Mitchell E et al. (2006) A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Journal of Clinical Oncology, 24 (Suppl.), 147s (abstract 3506).
61. Giantonio BJ, Catalano PJ, Meropol NJ et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Journal of Clinical Oncology, 23(Suppl.), 1s (abstract 2).
62. Ryan AM, Eppler DB, Hagler KE et al. (1999) Preclinical safety evaluation of rhuMABVEGF, an antiangiogenic humanized monoclonal antibody. Toxicologic Pathology, 27, 78-86.
63. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 21, 60-65.
64. Rivera F, Cunningham D, Michael M et al. (2006) Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI, and capecitabine for mCRC: First BEATrial. Proceedings of the World Congress on Gastrointestinal Cancer, Abstract O-017.
65. Hedrick E, Kozloff M, Hainsworth J et al. (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). Journal of Clinical Oncology, 24(Suppl.), 155s (abstract 3536).
66. Henry TD, Rocha-Singh K, Isner JM et al. (2001) Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. American Heart Journal, 142, 872-880.
67. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. Journal of Biological Chemistry, 278, 12605-12608.
68. Ostendorf T, Kunter U, Eitner F et al. (1999) VEGF(165) mediates glomerular endothelial repair. Journal of Clinical Investigation, 104, 913-923.
69. Skillings JR, Johnson DH, Miller K et al. (2005) Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Journal of Clinical Oncology, 25(Suppl.), 196s (abstract 3019).
70. Hambleton J, Novotny WF, Hurwitz H et al. (2004) Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Journal of Clinical Oncology, 22(Suppl.), 252s (abstract 3528).
71. Zachary I (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. American Journal of Physiology Cell Physiology, 280, C1375-C1386.
72. Scappaticci FA, Fehrenbacher L, Cartwright T et al. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Journal of Surgical Oncology, 91, 173-180.
73. Gruenberger T, Gruenberger B, Scheithauer W(2006) Neoadjuvant therapy with bevacizumab. Journal of Clinical Oncology, 24, 2592-2593.
74. Berry S, Michael M, Kretzschmar A et al. (2006) Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. Presented at: 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, CA, abstract 245.
75. DiBartolomeo M, Van Cutsem E, Michael M et al. (2006) Feasibility of metastasectomy after bevacizumab and chemotherapy in metastatic colorectal cancer - preliminary results from First BEAT. Proceedings of the World Congress on Gastrointestinal Cancer, Abstract P-209.
76. Johnson DH, Fehrenbacher L, Novotny WF et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 22, 2184-2191.
77. Sugrue M, Kozloff M, Hainsworth J et al. (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Journal of Clinical Oncology, 24(Suppl.), 154s (abstract 3535).
78. Miller KD, Chap LI, Holmes FA et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology, 23, 792-799.
79. Chawla A, Holmgren E, Nelson B et al. (2005) Impact of bevacizumab plus 5-FU/LV with or without irinotecan on quality of life in patients with metastatic colorectal cancer. European Journal of Cancer Supplements, 3, 367 (abstract 1274).
80. Saltz LB, Chung KY, Timoney J, Park V, Hollywood E (2006) Simplification of bevacizumab (bev) administration: do we need 90, 60, or even 30 minute infusion times? Journal of Clinical Oncology, 24 (Suppl.), 156s (abstract 3542).
81. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in healthcare resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health, 7, 518-528.
82. Mayer RJ (2004) Two steps forward in the treatment of colorectal cancer. New England Journal of Medicine, 350, 2406-2408.
83. Hecht JR, Trarbach T, Jaeger E et al. (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Journal of Clinical Oncology, 23(Suppl.), 2s (abstract LBA3).
84. Koehne C, Bajetta E, Lin E et al. (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). Journal of Clinical Oncology, 24(Suppl.), 148s (abstract 3508).